Scope and claims analysis for U.S. Patent 12,427,141 (BYL719/alphapalisib for PIK3CA-related overgrowth spectrum, PROS)
Executive summary: U.S. Patent 12,427,141 claims oral BYL719 (a.k.a. alpelisib; marketed as Piqray) for reversing multi-organ/multi-tissue overgrowth in PROS patients with somatic PIK3CA mosaic mutations. The independent claims are narrow by patient framing (adult vs child), therapy framing (starting doses tied to age), and clinical definition of PROS (explicitly excludes “isolated venous malformation” while emphasizing multi-organ overgrowth). Dependent claims narrow further to specific PIK3CA variants (H1047R, E542K, E545K), rapamycin non-responsiveness, enumerated PROS subtypes (including CLOVES and Klippel-Trenaunay), and a broad symptoms list. This creates a claims structure that is most likely to deter “same drug, same indication, same dosage regimen” generic and biosimilar-style launch designs, while leaving more room for challengers via design-around through different dosing, different PROS sub-classification, or different therapeutic endpoints.
What does U.S. Patent 12,427,141 protect for BYL719 in PROS?
Core protection: A method claim covering treatment of PIK3CA-related overgrowth spectrum (PROS) caused by somatic mosaic PIK3CA mutations, where the PROS is multi-organ or multi-tissue overgrowth and is not an isolated venous malformation, using oral BYL719 at starting doses that depend on patient age, to reverse overgrowth.
Independent claim architecture
U.S. Patent 12,427,141 has two main independent claims, each anchored to a distinct patient group and starting dose:
-
Claim 1 (adult):
- Patient: adult with PROS
- PROS etiology: somatic mosaic mutation in PIK3CA causing overgrowth of multiple organs or tissues
- Scope constraint: PROS is not isolated venous malformation
- Drug: BYL719 orally
- Dosage: starting dose 250 mg daily
- Outcome: reversing multi-organ/multi-tissue overgrowth
-
Claim 8 (child):
- Patient: child with PROS
- Etiology and scope constraint: same framing (somatic mosaic mutation; multi-organ/multi-tissue; not isolated venous malformation)
- Drug: BYL719 orally
- Dosage: starting dose 50 mg daily
- Outcome: reversing multi-organ/multi-tissue overgrowth
Key claim terms that define enforceable scope
These terms drive practical infringement and design-around risk:
- “PROS disorder”: broad umbrella constrained by the additional requirement that it is multi-organ/multi-tissue overgrowth due to a somatic mosaic mutation.
- “somatic mosaic mutation”: requires that the mutation is present in the affected tissue context, not germline.
- “overgrowth of multiple organs or tissues”: excludes purely single-issue manifestations and supports argument that “localized” cases fall outside scope.
- “not an isolated venous malformation”: a carve-out that can matter in clinical coding and payer policies.
- “reversing the overgrowth”: an outcome-based functional term. It is not a quantified metric in the claim excerpt you provided, which increases litigation interpretive room.
- “starting dose of X mg daily”: dosing language is a major infringement handle. It ties claim coverage to initiation dosing rather than maintenance dosing.
Which specific PIK3CA mutations and PROS subtypes does U.S. 12,427,141 cover?
Answer: The dependent claims add two layers of specificity: (1) restricting the somatic PIK3CA variants to a defined set, and (2) enumerating named PROS syndromes.
PIK3CA variant limitation (dependent claims)
- Claims 2 and 9 limit the somatic mosaic mutation to:
Practical effect: if a patient’s somatic mosaic mutation falls outside these three codon-change variants, an accused method may have stronger non-infringement positions for claims 2/9 (but not necessarily for claims 1/8 if the broader somatic mosaic mutation requirement is satisfied).
PROS subtype enumeration (dependent claims)
-
Claims 4, 5, 6 specify PROS disorders including:
- Fibroadipose overgrowth
- Megalencephaly-capillary malformation syndrome
- CLOVES syndrome
- Hemihyperplasia multiple lipomatosis
- Klippel-Trenaunay syndrome
-
Claims 5 and 12 further narrow to congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome.
-
Claims 6 and 13 narrow to Klippel-Trenaunay syndrome.
Practical effect: these enumerations can support narrower infringement theories, but they also create a pathway for challengers who treat outside those named subtypes, depending on how PROS is diagnosed and labeled in practice.
Is the patent limited to rapamycin non-responsiveness?
Answer: Yes, via dependent claims.
- Claim 3 (adult) and Claim 10 (child) require that the PROS disorder is “not responsive to treatment with rapamycin.”
Practical effect:
- Claims 3 and 10 are narrower than claims 1 and 8.
- A method performed without a rapamycin non-response predicate would not land in claim 3/10, though it could still potentially infringe claims 1/8 if all other limitations are met.
What symptoms and clinical endpoints are listed for PROS treatment in 12,427,141?
Answer: The patent lists a broad symptom/treatment endpoint universe that includes vascular, renal, neurologic, orthopedic, and tissue-growth descriptors.
- Claims 7 and 14 list a symptom selected from:
- edema
- venous dilation
- vascular tumors
- elevated brain natriuretic peptide blood level
- proteinuria
- kidney dysfunction
- overgrown tissue
- dysregulated adipose tissue
- scoliosis
- enlarged bony structures without progressive bony overgrowth
- benign tumors
- megalencephaly-capillary malformation
- lipomatous asymmetric overgrowth of the trunk
- epidermal nevi
- lymphatic malformation
- muscle hypertrophy
- liver steatosis
- spleen disorganization
Practical effect:
- This is unusually broad for a method claim. It supports enforcement based on treating for symptomatic improvement even if the broad “reversing overgrowth” is interpreted flexibly.
- The list can also reduce defendants’ ability to argue that only a narrow anatomical endpoint qualifies.
How does “starting dose” change infringement risk and design-around options?
Answer: The claim is most vulnerable on dosing initiation, because both independent claims explicitly fix dose levels.
- Adults: 250 mg daily starting dose (Claim 1)
- Children: 50 mg daily starting dose (Claim 8)
Design-around levers implied by the claim language
Because the excerpt ties protection to a “starting dose,” potential non-infringement strategies include:
- initiating at a different starting dose (if clinically permissible and used in practice)
- using a different initiation regimen that the accused method can argue does not literally meet “starting dose of 250 mg” or “starting dose of 50 mg”
- shifting the method emphasis to a different therapeutic outcome framed as not “reversing overgrowth” in the claimed multi-organ/multi-tissue setting
These levers are fact-dependent, but the dosing language is a strong litigation focal point.
What is the overall claim scope: broad method vs. narrow dependent claim fences?
Answer: Independent claims are broad on PROS inclusion and somatic mosaic etiology but narrow on (i) patient age framing, (ii) multi-organ/multi-tissue overgrowth, (iii) exclusion of isolated venous malformation, and (iv) dosing initiation. Dependent claims add narrower biological and clinical predicates.
Scope map
-
Claims 1/8 (independent):
- Adult vs child
- PROS due to somatic mosaic PIK3CA mutation
- Multi-organ/multi-tissue overgrowth
- Not isolated venous malformation
- Oral BYL719 at starting dose (250 mg or 50 mg)
- Reverse overgrowth
-
Claims 2/9 (variant-specific): restrict PIK3CA mutation to H1047R/E542K/E545K.
-
Claims 3/10 (rapamycin non-responsive): restrict by prior non-response.
-
Claims 4-6/11-13 (subtype-specific): restrict to enumerated syndromes.
-
Claims 7/14 (symptom list): restrict to treating a symptom selected from the enumerated list.
What patents likely sit around U.S. 12,427,141 in the BYL719/alphapalisib PROS estate?
Answer: Based on the claims’ structure, U.S. 12,427,141 is part of a PROS-focused method-of-use cluster that typically coexists with:
- core compound patents on BYL719 itself,
- earlier-on-target or genotype/diagnostic selection patents tied to PIK3CA mosaic mutations,
- formulation and dosing patents (oral tablets, dose strengths, and regimen),
- additional method-of-use patents for specific PROS subtypes and/or patient populations.
However, without the application number, assignee, filing dates, priority chain, and the full specification claim set, it is not possible to produce a complete, accurate “around-the-number” landscape (specific patent numbers, expiration dates, and Orange Book listings).
What does the claim set imply about likely infringement theories in litigation?
Answer: The claims are written to enable multiple infringement routes:
1) Direct method infringement via prescribed starting-dose regimen
If a prescriber administers (or induces administration of) BYL719 according to the method including starting dose and PROS criteria, infringement theory can be built around:
- adult or child classification
- PROS diagnosis meeting the multi-organ/multi-tissue and “not isolated venous malformation” constraints
- somatic mosaic PIK3CA mutation confirmation
- oral BYL719 initiation at the claimed starting dose
- clinical reversal evidence used to satisfy “reversing the overgrowth”
2) Dependent-claim tightening for higher evidentiary comfort
Claims 2/9, 3/10, and 4-6/11-13 provide narrower predicates that may match clinical trial inclusion criteria and molecular testing panels, making infringement arguments more concrete if the treated patient matches the listed variant and syndrome.
3) Symptom list supports “treating a symptom” framing
Claims 7/14 allow a method argument anchored on symptom improvement even if the “reversing overgrowth” concept becomes contested. The symptom list includes vascular, renal, orthopedic, skin, neurologic, lymphatic, and adipose/tissue descriptors.
What generic entry risks exist if BYL719 is off-patent for other indications?
Answer: If the active ingredient is generic, method-of-use patent coverage can still create launch and litigation risk because the claims are not directed to composition. A generic could potentially sell BYL719, but would be constrained by:
- induced infringement exposure tied to doctors/pharmacies following the claimed starting-dose initiation for PROS patients with the claimed diagnostic predicates.
Risk severity depends on whether enforcement is pursued against prescribers and dispensing entities and how the method claims are construed, but the “starting dose” and “not isolated venous malformation” limitations are practical levers for both sides.
How does this patent likely interact with FDA labeling and PROS approvals?
Answer: The claims track the regulatory logic of molecularly defined, mosaic-driven PROS treatment with oral BYL719 in adults and children at distinct dosing anchors. If FDA-approved labeling includes PROS treatment directions aligned to the claimed starting doses and patient framing, the method claims become easier to map to real-world practice. If labeling differs (dose titration schedules, different starting doses, different patient selection language), mapping may be more contested.
(Your prompt does not provide FDA label text or Orange Book listings, so no specific status callouts can be made here.)
Key Takeaways
- U.S. Patent 12,427,141 is a method-of-treatment IP asset for BYL719 (oral) in PROS defined by somatic mosaic PIK3CA mutation and multi-organ/multi-tissue overgrowth, with an explicit exclusion of isolated venous malformation.
- The independent claims are separated by patient age and tie coverage to starting doses: 250 mg daily (adults) and 50 mg daily (children).
- Dependent claims narrow to:
- PIK3CA variants H1047R/E542K/E545K
- rapamycin non-responsiveness
- enumerated PROS syndromes including CLOVES and Klippel-Trenaunay
- a wide symptom/treatment endpoint list spanning vascular, renal, adipose/tissue, orthopedic, lymphatic, skin, and benign tumor descriptors.
- Enforcement leverage is strongest where real-world treatment matches the diagnostic predicates and starting-dose initiation language.
FAQs
- How do courts usually construe “reversing the overgrowth” in method claims for PROS?
- Does the “not an isolated venous malformation” limitation create a clear carve-out for patients coded as VMs only?
- If a PROS patient has a non-H1047R/E542K/E545K PIK3CA variant, which claims remain strongest?
- Can a different BYL719 initiation regimen avoid infringement if maintenance dosing matches?
- Which claim features would be most important for a litigation infringement chart: patient age, starting dose, mosaic confirmation, or PROS subtype labeling?
References
- United States Patent No. 12,427,141.
